Patents by Inventor Evelyn DE TAVERNIER

Evelyn DE TAVERNIER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HIGHLY POTENT ISVD COMPOUNDS CAPABLE OF SUBSTITUTING FOR FVIII(A)
    Publication number: 20240067944
    Abstract: The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.
    Type: Application
    Filed: July 7, 2023
    Publication date: February 29, 2024
    Applicant: Novo Nordisk A/S
    Inventors: Andreas Vegge, Daniele Granata, Eva Johansson, Jais Rose Bjelke, Jacob Lund, Philip Jonas Sassene, Per J. Greisen, Thomas Egebjerg, Evelyn De Tavernier, Soren Steffensen, Marie-Ange Buyse, Frantisek Hubalek, Simone Fulle, Mathias Norrman
  • FACTOR X BINDERS ENHANCING FX ACTIVATION
    Publication number: 20230416404
    Abstract: The application relates to unique FX binding molecules, such as antibodies and fragments thereof which are useful in the treatment of haemophilia.
    Type: Application
    Filed: September 6, 2023
    Publication date: December 28, 2023
    Inventors: Jacob Lund, Karina Thorn, Mikkel Nors Harndahl, Marie-Ange Buyse, Evelyn De Tavernier, Soren Steffensen
  • Factor X binders enhancing FX activation
    Patent number: 11787874
    Abstract: The application relates to unique FX binding molecules, such as antibodies and fragments thereof which are useful in the treatment of haemophilia.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: October 17, 2023
    Assignee: Novo Nordisk A/S
    Inventors: Jacob Lund, Karina Thorn, Mikkel Nors Harndahl, Marie-Ange Buyse, Evelyn De Tavernier, Soren Steffensen
  • VEGF-BINDING MOLECULES
    Publication number: 20220363744
    Abstract: VEGF-binding molecules, preferably VEGF-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF-mediated effects on angiogenesis. Nucleic acids encoding VEGF-binding molecules, host cells and methods for preparing same.
    Type: Application
    Filed: June 21, 2022
    Publication date: November 17, 2022
    Inventors: Andreas GSCHWIND, Eric BORGES, Joachim BOUCNEAU, Evelyn DE TAVERNIER, Joost KOLKMAN, Pascal MERCHIERS
  • PcrV binding single variable domain antibodies
    Patent number: 11312788
    Abstract: Polypeptides are provided that are capable of significantly inhibiting and/or neutralizing P. aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: April 26, 2022
    Assignee: Ablynx N.V.
    Inventors: Evelyn De Tavernier, Ann Union, Bruno Dombrecht, Guy Hermans, Erika Morizzo
  • FACTOR X BINDERS ENHANCING FX ACTIVATION
    Publication number: 20210054097
    Abstract: The application relates to unique FX binding molecules, such as antibodies and fragments thereof which are useful in the treatment of haemophilia.
    Type: Application
    Filed: November 15, 2018
    Publication date: February 25, 2021
    Inventors: Jacob Lund, Karina Thorn, Mikkel Nors Harndahl, Marie-Ange Buyse, Evelyn De Tavernier, Soren Steffensen
  • VEGF-BINDING MOLECULES
    Publication number: 20200308267
    Abstract: VEGF-binding molecules, preferably VEGF-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF-mediated effects on angiogenesis. Nucleic acids encoding VEGF-binding molecules, host cells and methods for preparing same.
    Type: Application
    Filed: June 17, 2020
    Publication date: October 1, 2020
    Inventors: Andreas GSCHWIND, Eric BORGES, Joachim BOUCNEAU, Evelyn DE TAVERNIER, Joost KOLKMAN, Pascal MERCHIERS
  • PSEUDOMONAS AERUGINOSA PCRV BINDING SINGLE VARIABLE DOMAIN ANTIBODIES
    Publication number: 20200190217
    Abstract: Polypeptides are provided that are capable of significantly inhibiting and/or neutralizing P. aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.
    Type: Application
    Filed: July 17, 2018
    Publication date: June 18, 2020
    Applicant: Ablynx N.V.
    Inventors: Evelyn De Tavernier, Ann Union, Bruno Dombrecht, Guy Hermans, Erika Morizzo
  • PSEUDOMONAS AERUGINOSA PCRV BINDING SINGLE VARIABLE DOMAIN ANTIBODIES
    Publication number: 20190055322
    Abstract: Polypeptides are provided that are capable of significantly inhibiting and/or neutralizing P. aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.
    Type: Application
    Filed: July 17, 2018
    Publication date: February 21, 2019
    Applicant: Ablynx N.V.
    Inventors: Evelyn De Tavernier, Ann Union, Bruno Dombrecht, Guy Hermans, Erika Morizzo
  • Pseudomonas aeruginosa PCRV binding single variable domain antibodies
    Patent number: 10072098
    Abstract: Polypeptides are provided that are capable of significantly inhibiting and/or neutralizing P aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: September 11, 2018
    Assignee: Ablynx N.V.
    Inventors: Evelyn De Tavernier, Ann Union, Bruno Dombrecht, Guy Hermans, Erika Morizzo
  • VEGF-BINDING MOLECULES
    Publication number: 20180201671
    Abstract: VEGF-binding molecules, preferably VEGF-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF-mediated effects on angiogenesis. Nucleic acids encoding VEGF-binding molecules, host cells and methods for preparing same.
    Type: Application
    Filed: December 5, 2017
    Publication date: July 19, 2018
    Inventors: Andreas GSCHWIND, Eric BORGES, Joachim BOUCNEAU, Evelyn DE TAVERNIER, Joost KOLKMAN, Pascal MERCHIERS
  • VEGF-BINDING MOLECULES
    Publication number: 20160200806
    Abstract: VEGF-binding molecules, preferably VEGF-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF-mediated effects on angiogenesis. Nucleic acids encoding VEGF-binding molecules, host cells and methods for preparing same.
    Type: Application
    Filed: December 18, 2015
    Publication date: July 14, 2016
    Inventors: Andreas GSCHWIND, Eric BORGES, Joachim BOUCNEAU, Evelyn DE TAVERNIER, Joost KOLKMAN, Pascal MERCHIERS
  • PSEUDOMONAS AERUGINOSA PCRV BINDING SINGLE VARIABLE DOMAIN ANTIBODIES
    Publication number: 20150044215
    Abstract: Polypeptides are provided that are capable of significantly inhibiting andor neutralizing P aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the “first” immunoglobulin single variable domain and the “second” immunoglobulin single variable domain have different paratopes.
    Type: Application
    Filed: March 4, 2013
    Publication date: February 12, 2015
    Applicant: Ablynx N.V.
    Inventors: Evelyn De Tavernier, Ann Union, Bruno Dombrecht, Guy Hermans, Erika Morizzo
  • BISPECIFIC BINDING MOLECULES FOR ANTI-ANGIOGENESIS THERAPY
    Publication number: 20140120095
    Abstract: Bispecific binding molecules, in particular immunoglobulin single variable domains such as VHHs and domain antibodies, comprising a VEGF-binding component and a DII4-binding component in one molecule. Pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF- and DII4-mediated effects on angiogenesis. Nucleic acids encoding the bispecific binding molecules, host cells and methods for preparing same.
    Type: Application
    Filed: March 22, 2013
    Publication date: May 1, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Eric BORGES, Andreas GSCHWIND, Joachim BOUCNEAU, Evelyn DE TAVERNIER, Joost KOLKMAN, Pascal MERCHIERS, Diane VAN HOORICK
  • VEGF-BINDING MOLECULES
    Publication number: 20120225081
    Abstract: VEGF-binding molecules, preferably VEGF-binding immunoglobulin single variable domains like VHHs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF-mediated effects on angiogenesis. Nucleic acids encoding VEGF-binding molecules, host cells and methods for preparing same.
    Type: Application
    Filed: September 1, 2011
    Publication date: September 6, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Andreas GSCHWIND, Eric BORGES, Joachim BOUCNEAU, Evelyn DE TAVERNIER, Joost KOLKMAN, Pascal MERCHIERS
  • DLL4-BINGING MOLECULES
    Publication number: 20110195494
    Abstract: DII4-binding molecules, preferably DII4-binding immunoglobulin single variable domains like VHHs and VHs, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with DII4-mediated effects on angiogenesis. Bispecific DII4-binding molecules that also bind to VEGF-A. Nucleic acids encoding DII4-binding molecules, host cells and methods for preparing same.
    Type: Application
    Filed: September 30, 2010
    Publication date: August 11, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Eric BORGES, Andreas GSCHWIND, Joachim BOUCNEAU, Evelyn DE TAVERNIER, Joost KOLKMAN, Pascal MERCHIERS, Diane VAN HOORICK
  • BISPECIFIC BINDING MOLECULES FOR ANTI-ANGIOGENESIS THERAPY
    Publication number: 20110172398
    Abstract: Bispecific binding molecules, in particular immunoglobulin single variable domains such as VHHs and domain antibodies, comprising a VEGF-binding component and a Dll4-binding component in one molecule. Pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF- and Dll4-mediated effects on angiogenesis. Nucleic acids encoding the bispecific binding molecules, host cells and methods for preparing same.
    Type: Application
    Filed: September 30, 2010
    Publication date: July 14, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Eric BORGES, Andreas GSCHWIND, Joachim BOUCNEAU, Evelyn DE TAVERNIER, Joost KOLKMAN, Pascal MERCHIERS, Diane VAN HOORICK